Institute for Therapeutics Discovery and Development

Organization profile

Organization profile

Institute for Therapeutics Discovery and Development (ITDD; Gunda I. Georg, Ph.D., Director, Vadim J. Gurvich, Ph.D., Associate Director) is a research center within the College of Pharmacy that would enable creating an almost complete line from drug discovery to drug development to clinical trials within the University of Minnesota. The Institute's purpose is to conduct research, provide education and offer scientific services to research and business communities in the area of drug discovery and development. The Institute greatly enhances the research capabilities of the University of Minnesota by allowing translation of the biological discoveries to new therapies and bringing drugs to market. The Institute consists of four scientific cores - Medicinal Chemistry, High-Throughput Screening, Lead and Probe Discovery, and Chemical Process Development. The Institute offers a variety of services including drug discovery, HTS and assay development (assay capabilities include absorbance, FRET, fluorescence, luminescence, cell based reporter & viability assays, FP, and high content image analysis assays), computational drug design, lead identification and optimization, medicinal chemistry, organic chemistry, chemical libraries development, chemical process development, scale up, API synthesis under cGMP conditions, CMC support for IND applications, protein purification, analytical services, and others.

Fingerprint Dive into the research topics where Institute for Therapeutics Discovery and Development is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.

Assays Chemical Compounds
Prodrugs Medicine & Life Sciences
Gases Chemical Compounds
Opioid Analgesics Medicine & Life Sciences
Throughput Chemical Compounds
Telomerase Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Oxycodone Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Profiles

No photo of Peter I Dosa

Peter I Dosa

Person: Academic Professional

20122022

Projects 2005 2023

Caspase 2
KATP Channels
Intraocular Pressure

Research Output 1996 2019

3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity

Xue, L., Shi, D. H., Harjani, J. R., Huang, F., Beveridge, J. G., Dingjan, T., Ban, K., Diab, S., Duffy, S., Lucantoni, L., Fletcher, S., Chiu, F. C. K., Blundell, S., Ellis, K., Ralph, S. A., Wirjanata, G., Teguh, S., Noviyanti, R., Chavchich, M., Creek, D. & 10 others, Price, R. N., Marfurt, J., Charman, S. A., Cuellar, M. E., Strasser, J. M., Dahlin, J. L., Walters, M. A., Edstein, M. D., Avery, V. M. & Baell, J. B., Jan 1 2019, In : Journal of Medicinal Chemistry.

Research output: Contribution to journalArticle

Antimalarials
Plasmodium falciparum
Plasmodium vivax
Triazines
Parasitemia
3 Citations (Scopus)

A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats

Raleigh, M. D., Baruffaldi, F., Peterson, S. J., Le Naour, M., Harmon, T. M., Vigliaturo, J. R., Pentel, P. R. & Pravetoni, M., Feb 1 2019, In : Journal of Pharmacology and Experimental Therapeutics. 368, 2, p. 282-291 10 p.

Research output: Contribution to journalArticle

Fentanyl
Vaccines
Heroin
Respiratory Insufficiency
Opioid Analgesics

111 In-DANBIRT in Vivo Molecular Imaging of Inflammatory Cells in Atherosclerosis

Mota, R., Campen, M. J., Cuellar, M. E., Garver, W. S., Hesterman, J., Qutaish, M., Daniels, T., Nysus, M., Wagner, C. R. & Norenberg, J. P., Jan 1 2018, In : Contrast Media and Molecular Imaging. 2018, 6508724.

Research output: Contribution to journalArticle

Molecular Imaging
High Fat Diet
Atherosclerotic Plaques
Atherosclerosis
Ozone